TED Ted Baker Plc

RNS Number:7629P
Tepnel Life Sciences PLC
11 March 2008



FOR IMMEDIATE RELEASE

Tepnel Life Sciences launches biopharmaceutical and genotyping services at Livingston



Manchester, U.K, 11 March 2008 Tepnel Life Sciences (AIM: TED), the
international Molecular Diagnostics and Research Products & Services group,
today announced the completion of Phase II construction and launch of
biopharmaceutical and clinical genotyping services at its Livingston facility.



Clinical genotyping is a growing area of genetic analysis with the potential to
lead to personalised medicine.  It works by linking a patient's genetic makeup
to their response to particular drugs, enabling specialists to establish which
treatments will best benefit an individual.  Clinical genotyping also allows for
the early identification of genetic disease.



The introduction of biopharmaceutical and genotyping services will give Tepnel
access to these rapidly-growing markets, enabling the Company to offer complete
service packages to clients across these two broad areas.



With these new capabilities, Tepnel will simultaneously increase the product
development capabilities of its Molecular Diagnostics division and become one of
the UK's leading providers to the pharmaceutical and molecular diagnostics
sectors.



Tepnel's Chief Executive Officer, Ben Matzilevich, said: "The completion of our
state-of-the-art pharmaceutical testing facility in Livingston, Scotland will
enable us to establish clinical genotyping and biopharmaceutical operations and
expand our small molecule pharmaceutical service capabilities.  These
capabilities are key to our long term growth strategy.



"We look forward to providing our pharmaceutical customers with a full line of
in-house services that increases efficiency, maintains sample integrity and
minimises the risks associated with inter-laboratory transfer."



Officially opened in September 2007, the �5 million Livingston pharmaceutical
testing facility was part funded by Scottish Enterprise, Edinburgh and Lothian.



                                     -Ends-



For further information:



Tepnel Life Sciences plc

Ben Matzilevich, CEO

Carol Smith

Tel: 0161 946 2200



Capital MS&L

Mary Clark or Catie Corcoran

Tel: +44 20 7307 5330


Seymour Pierce Limited
Mark Percy
Tel: +44 20 7107 8000



Notes to Editors:


About Tepnel Life Sciences plc - Tepnel Life Sciences plc (AIM: TED) is a
UK-based international life sciences products and services group with two
divisions, Molecular Diagnostics and Research Products & Services.  The Company
has laboratories, manufacturing and operations in the USA, UK and France with
over 200 employees.



Tepnel provides test kits, reagents and services to two highly synergistic
markets, these being Molecular Diagnostics and Biomedical Research.



The Company's strategy has been to identify high growth niche opportunities
within these multi-billion pound markets.  Tepnel focuses on these opportunities
with internally developed products, patents, expertise and know-how as well as
strategic acquisitions, to develop a leadership position within these defined
market segments.








                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

MSCFKKKQPBKDOND

Ted Baker (LSE:TED)
Historical Stock Chart
From Jun 2024 to Jul 2024

Ted Baker (LSE:TED)
Historical Stock Chart
From Jul 2023 to Jul 2024